MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Cue Biopharma ROCE Ratio 2011-2025 | CUE
Annual ROCE Ratio Cue Biopharma
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -237.16 | -140.62 | -81.03 | -66.74 | -54.13 | -61.33 | -98.85 | -37.71 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -37.71 | -237.16 | -97.2 |
Quarterly ROCE Ratio Cue Biopharma
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -174.39 | -165.08 | -109.54 | -136.3 | -130.93 | -80.47 | -102.2 | -97.16 | -89.69 | -65.65 | -86.15 | -84.91 | -77.14 | -52.59 | -65.43 | -57.78 | -57.51 | -43.17 | -56.17 | -56.33 | -59.37 | -50.84 | -88.4 | -112.96 | -118.04 | -81.69 | -89.86 | -60.47 | -45.64 | -20.77 | -20.77 | -12.6 | -5.44 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -5.44 | -174.39 | -77.44 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AC Immune SA
ACIU
|
-27.26 | $ 2.8 | 2.19 % | $ 229 M |  Schweiz |
 |
ADiTx Therapeutics
ADTX
|
-5611.16 | $ 2.49 | -11.39 % | $ 32.8 K |  USA |
 |
Aeterna Zentaris
AEZS
|
-29.95 | - | 5.93 % | $ 314 M |  Canada |
 |
Abeona Therapeutics
ABEO
|
-317.92 | $ 4.59 | -4.08 % | $ 98.1 M | USA |
 |
ARCA biopharma
ABIO
|
-23.06 | - | 1052.0 % | $ 415 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-60.13 | - | - | $ 26.5 M | USA |
 |
Akouos
AKUS
|
-37.16 | - | 0.23 % | $ 488 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
10.81 | $ 12.12 | -1.58 % | $ 3.74 B | USA |
 |
Axcella Health
AXLA
|
-1848.9 | - | -16.42 % | $ 249 M | USA |
 |
Acer Therapeutics
ACER
|
146.85 | - | 2.71 % | $ 14 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
127.52 | $ 5.37 | -20.68 % | $ 194 M | USA |
 |
Atreca
BCEL
|
-34.9 | - | -11.76 % | $ 5.79 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
163.63 | - | -2.5 % | $ 5.88 M | USA |
 |
argenx SE
ARGX
|
-211.69 | $ 919.62 | 2.76 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
-45.89 | $ 203.0 | -3.72 % | $ 5 B |  Danmark |
 |
Achieve Life Sciences
ACHV
|
-90.77 | $ 4.64 | -0.32 % | $ 92 M | USA |
 |
BioDelivery Sciences International
BDSI
|
19.77 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-15.33 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Acorda Therapeutics
ACOR
|
167.74 | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 3.36 | 2.73 % | $ 8.08 B |  Australia |
 |
Acasti Pharma
ACST
|
-25.04 | - | 4.01 % | $ 150 M | Canada |
 |
Bellerophon Therapeutics
BLPH
|
-883.35 | - | -74.18 % | $ 955 K | USA |
 |
BioLineRx Ltd.
BLRX
|
-104.07 | $ 3.29 | -1.5 % | $ 908 M |  Israel |
 |
BioMarin Pharmaceutical
BMRN
|
8.56 | $ 54.27 | -1.38 % | $ 10.3 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-353.66 | - | -15.15 % | $ 60.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
17.36 | - | - | $ 40.3 B | USA |
 |
Baudax Bio
BXRX
|
234.36 | - | 0.59 % | $ 63 K | USA |
 |
AbbVie
ABBV
|
274.8 | $ 224.99 | -0.01 % | $ 398 B | USA |
 |
Cara Therapeutics
CARA
|
-212.83 | - | -3.03 % | $ 260 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-34.79 | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
-45.41 | - | - | $ 3.74 B | USA |
 |
BioNTech SE
BNTX
|
-4.81 | $ 96.22 | -1.21 % | $ 27.2 B |  Germany |
 |
Codiak BioSciences
CDAK
|
-129.99 | - | -55.98 % | $ 2.15 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
-80.19 | $ 18.75 | -0.48 % | $ 2.76 B | USA |
 |
Avid Bioservices
CDMO
|
-30.68 | - | - | $ 789 M | USA |
 |
BioXcel Therapeutics
BTAI
|
72.23 | $ 1.92 | -7.01 % | $ 4.87 M | USA |
 |
Biogen
BIIB
|
31.45 | $ 179.76 | 1.11 % | $ 26.2 B | USA |
 |
Cerevel Therapeutics Holdings
CERE
|
-66.38 | - | - | $ 7.29 B | USA |
 |
ContraFect Corporation
CFRX
|
545.12 | - | -5.16 % | $ 5.39 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-61.36 | - | -1.52 % | $ 24.7 M | USA |
 |
Beam Therapeutics
BEAM
|
-56.65 | $ 23.52 | -2.22 % | $ 1.94 B | USA |
 |
AbCellera Biologics
ABCL
|
-24.52 | $ 3.45 | -0.72 % | $ 1.02 B | Canada |
 |
Cabaletta Bio
CABA
|
-31.61 | $ 2.37 | -2.67 % | $ 2.77 M | USA |
 |
Clearside Biomedical
CLSD
|
156.13 | - | - | $ 25.3 M | USA |
 |
Celsion Corporation
CLSN
|
-450.78 | - | -6.63 % | $ 13.9 M | USA |
 |
Clovis Oncology
CLVS
|
80.97 | - | -7.23 % | $ 13 M | USA |
 |
Advaxis
ADXS
|
429.74 | - | -9.65 % | $ 45.9 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-88.5 | - | - | $ 231 M | USA |
 |
Chimerix
CMRX
|
-48.21 | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
-69.06 | - | - | $ 401 M | USA |